1-(4-(2,4,5-Trimethylphenyl)thiazol-2-yl)guanidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(4-(2,4,5-Trimethylphenyl)thiazol-2-yl)guanidine
• 英文别名: 2-[4-(2,4,5-trimethylphenyl)-1,3-thiazol-2-yl]guanidine
• 化学式: C₁₃H₁₆N₄S
• 分子量: 260.36
• InChiKey: WYAZKKQMPDLFTG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  18
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  106
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR
  申请人：Grandel Roland

  公开号：US20100048582A1

  公开（公告）日：2010-02-25

  The invention relates to compounds of the formula (I) wherein the variables have meanings given in the claims and the description. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a medicament for the treatment of a medical disorder susceptible to the treatment with a 5HT 6 receptor ligand.

  本发明涉及公式（I）的化合物，其中变量的含义在权利要求书和说明书中给出。本发明还涉及使用公式I的化合物或其药学上可接受的盐来制备用于治疗可通过5HT6受体配体治疗的医疗紊乱的药物。
• HETEROCYCLIC ARYLSULPHONES SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE SEROTONIN 5HT6 RECEPTOR
  申请人：Grandel Roland

  公开号：US20090306175A1

  公开（公告）日：2009-12-10

  The invention relates to compounds of the formula (I) wherein the variables have meanings given in the claims and the description. The invention also relates to the use of a compound of the formula (I) or a pharmaceutically acceptable salt thereof for preparing a medicament for the treatment of a medical disorder susceptible to the treatment with a 5HT 6 receptor ligand.

  本发明涉及化合物(I)的公式，其中变量的含义在权利要求和说明书中给出。本发明还涉及使用公式(I)的化合物或其药学上可接受的盐来制备用于治疗可通过5HT6受体配体治疗的医学疾患的药物。
• Thiazol-Guanidine Derivatives Useful As A (Beta)-Related Pathologies
  申请人：Berg Stefan

  公开号：US20100298340A1

  公开（公告）日：2010-11-25

  This invention relates to novel compounds having the structural formula I below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.

  本发明涉及以下结构式I的新化合物，以及它们的药学上可接受的盐、组合物和使用方法。这些新化合物可用于治疗或预防认知障碍、阿尔茨海默病、神经退行性疾病和痴呆症。
• THIAZOL-GUANIDINE DERIVATIVES USEFUL AS A (BETA)- RELATED PATHOLOGIES
  申请人：AstraZeneca AB

  公开号：EP2010508A1

  公开（公告）日：2009-01-07
• US8497273B2
  申请人：——

  公开号：US8497273B2

  公开（公告）日：2013-07-30